MARK JOSEPH SARNO
Pilots at Fortuna Del Este, Escondido, CA

License number

California A4144750

Issued Date

Jul 2016

Expiration Date

Jul 2018

Professional information

President At Vision Biotechnology Consulting

Position:

Consultant at Orlucent, Consultant at Mesa Tech International, Inc., Scientific Advisory Board Member at Iris Molecular Diagnostics, Consultant at Millennium Laboratories, Consultant at Metabolon, Consultant at Trovagene, Inc., Consultant at Sequenom, Consultant at Arista Molecular Laboratories, Consultant at Luminex Corporation, Consultant at Stason Pharmaceuticals, Consultant at Iris Molecular Diagnostics, Consultant at Food and Drug Law, Consultant at Gen Probe, Consultant at Santarus Pharmaceuticals, Consultant at Qualigen Inc., Consultant at Toyota Tsusho America, Consultant at diaDexus, President at Vision Biotechnology Consulting (Sole Proprietorship)

Location:

Escondido, California

Industry:

Biotechnology

Work:

Orlucent - Palo Alto since Jul 2013 - Consultant Mesa Tech International, Inc. - San Diego since Jul 2013 - Consultant Iris Molecular Diagnostics since Jan 2012 - Scientific Advisory Board Member Millennium Laboratories - San Diego since Nov 2011 - Consultant Metabolon - North Carolina since Nov 2011 - Consultant Trovagene, Inc. since Sep 2011 - Consultant Sequenom since 2010 - Consultant Arista Molecular Laboratories since 2010 - Consultant Luminex Corporation since Apr 2009 - Consultant Stason Pharmaceuticals since Jan 2009 - Consultant Iris Molecular Diagnostics since 2006 - Consultant Food and Drug Law since 2006 - Consultant Gen Probe since 2004 - Consultant Santarus Pharmaceuticals since 2003 - Consultant Qualigen Inc. since 2003 - Consultant Toyota Tsusho America since 2002 - Consultant diaDexus since 2001 - Consultant Vision Biotechnology Consulting since Apr 1996 - President ADVENTRX Pharmaceuticals Dec 2009 - Jan 2012 - Consultant UpSpring Baby Sep 2009 - Mar 2011 - Consultant Cadence Pharmaceuticals Jun 2009 - 2010 - Consultant CovX 2008 - 2009 - Consultant Aviir, Inc. 2007 - 2009 - Consultant SGX Pharmaceuticals 2007 - 2008 - Consultant Medikinetics 2003 - 2008 - Consultant Cystic Fibrosis Foundation 2006 - 2007 - Consultant Applied Molecular Evolution 2006 - 2007 - Consultant La Jolla Pharmaceutical Company 2002 - 2007 - Consultant Kfx Medical 2006 - 2006 - Consultant CardioDynamics 2005 - 2006 - Consultant Chiltern International 2004 - 2006 - Consultant Metabasis Therapeutics 2005 - 2005 - Consultant ReliaLab 2004 - 2005 - Consultant Applied Imaging 2004 - 2005 - Consultant Metrika 2004 - 2005 - Consultant Maxim Pharmaceuticals 1999 - 2004 - Consultant Equidyne Systems, Inc. 1998 - 2004 - Consultant DiagnoCure 2003 - 2003 - Consultant Pacific Biometrics, Inc. 1997 - 2002 - Consultant NovaDx 1995 - 1996 - Director, Product Development Hybritech, Inc. 1986 - 1995 - Scientist

Education:

Concord Law School - Kaplan University 2005 - 2008
eJD, Patent Law, Bioethics, Medical Products Liability, etc. University of California, San Diego 1981 - 1983
BA, Biochemistry, cell biology, molecular genetics

Interests:

Running, playing drums, flying small airplanes, riding motorcycles, German Shepherd rescue

Honor & Awards:

2-Time Development Scientist of the Year winner at Hybritech, Inc.; Award for outstanding legal writing; Graduated Concord Law School with Honors

Membrane-Based Immunoassay Method

US Patent:

5395754, Mar 7, 1995

Filed:

Jul 31, 1992

Appl. No.:

7/923339

Inventors:

Paul P. Lambotte - San Diego CA
Robert C. Darter - San Diego CA
Mark J. Sarno - Escondido CA

Assignee:

Hybritech Incorporated - San Diego CA

International Classification:

G01N 33573

US Classification:

4356074

Abstract:

The present invention is directed to a membrane-based immunoassay method for an analyte of interest having at least two sterically separate antigenic sites. The method comprises providing a reactive membrane having a calibration zone and a test zone, wherein the calibration zone is characterized by having a predetermined amount of the analyte of interest immobilized via a first antibody as a first specific binding pair to a solid phase, the immobilized first binding pair being covalently cross-linked such that any remaining binding sites on said first immobilized antibody are substantially incapable of further specifically binding to any additional analyte, but at least some of said analyte is capable of specifically binding to a preselected amount of a labelled second antibody. The method further includes the steps of contacting the reactive membrane with a predetermined amount of sample and allowing any analyte in the test sample to become specifically bound to immobilized first antibody in the test zone; contacting the immobilized analyte in the test and calibrator zones with a labelled second antibody capable of binding to a second antigen site on the immobilized analyte; and determining the presence or amount of analyte in the test sample by comparing the amount of labelled second antibody specifically bound in the test zone versus the amount of labelled second antibody specifically bound in the calibration zone.

Method For Determining Likelihood Of Clinical Recurrence Or Clinically Stable Disease Of Prostate Cancer After Radical Prostatectomy

US Patent:

2012032, Dec 27, 2012

Filed:

Jun 5, 2012

Appl. No.:

13/489430

Inventors:

Robert E. Klem - Rancho Santa Fe CA, US
Russell Saunders - Carlsbad CA, US
Edward Jablonski - Escondido CA, US
Thomas H. Adams - Rancho Santa Fe CA, US
Mark J. Sarno - Escondido CA, US
Jonathan E. McDermed - Carlsbad CA, US

International Classification:

A61K 38/22, A61P 35/00, C12Q 1/68

US Classification:

514 97, 435 612

Abstract:

This invention describes compositions and methods for use in PSA assays having low functional sensitivity which are useful, for example, in the detection of early stage recurrence of prostate disease following treatment and in the determination of whether patients have early stage biochemical reoccurrence (ES-BCR) or stable disease.